Keyphrases
Congenital Coagulopathies
100%
Granulocyte Collection
50%
Concept Map
50%
Medical Student Learning
50%
Critically Ill Patients
50%
Activated Partial Thromboplastin Time (aPTT)
50%
Heparin
50%
Unfractionated Heparin
50%
Anti-factor Xa
50%
Activity Assay
50%
Bleeding Outcomes
50%
Major Bleeding Events
40%
Fibrinogen
33%
Congenital Deficiency
33%
Coagulation Factors
33%
Inherited Defect
33%
State Diagnosis
33%
State Management
33%
Congenital Bleeding Disorders
33%
Coagulation Mechanism
33%
V-factor
33%
Sex-linked Disorders
33%
Bleeding Risk
26%
Length of Hospital Stay
20%
X-factor
16%
Two-sex
16%
Granulocyte Concentrates
16%
Hemophilia B
16%
Concept Mapping
16%
Factor 9
16%
Protein Function
16%
Hemophilia
16%
Diagnostic Evaluation
16%
Population Prevalence
16%
Plasminogen Activator inhibitor-1 (PAI-1)
16%
Proteinase Inhibitor
16%
Diagnosis Management
16%
Autosomal Recessive
16%
Protein Components
16%
Prothrombin
16%
Clinical Presentation
16%
Deficiency State
16%
Clinical Management
16%
Number of Patients
16%
Risk Ratio
10%
Single Center
10%
Thrombotic Events
10%
Heparin Infusion
10%
Thrombotic Risk
10%
Individualized Approach
10%
Medicine and Dentistry
Coagulopathy
100%
Blood Clotting Factor
66%
Fibrinogen
66%
Granulocyte Collection
50%
Burkitt's Lymphoma
50%
Cancer Registry
50%
Systemic Therapy
35%
Protein Function
33%
Autosomal Recessive Inheritance
33%
Haemophilia B
33%
Factor V
33%
Proteinase Inhibitor
33%
Bleeding Disorder
33%
Haemophilia A
33%
Prothrombin
33%
Factor VII
33%
Clinical Management
33%
Disease
33%
Factor X
33%
Factor IX
33%
Plasminogen Activator Inhibitor
33%
Blood Clotting Factor 8
33%
Bleeding
33%
Factor XIII
33%
Prevalence
33%
Factor XI
33%
Overall Survival
28%
Disease Specific Survival
21%
Odds Ratio
21%
Comorbidity
7%
Chemoimmunotherapy
7%
Non-Hodgkin Lymphoma
7%
Elderly Population
7%
Diseases
7%
Second Cancer
7%
Pharmacology, Toxicology and Pharmaceutical Science
Bleeding
66%
Blood Clotting Factor 10a
50%
Heparin
50%
Thromboplastin
50%
Blood Clotting Disorder
50%
Blood Clotting Factor
33%
Fibrinogen
33%
Blood Clotting Factor 13
33%
Haemophilia B
33%
Haemophilia A
16%
Bleeding Disorder
16%
Blood Clotting Factor 7
16%
Fibrinolytic Agent
16%
Blood Clotting Factor 10
16%
Prevalence
16%
Blood Clotting Factor 9
16%
Blood Clotting Factor 8
16%
Blood Clotting Factor 5
16%
Plasminogen Activator Inhibitor
16%
Prothrombin
16%
Proteinase Inhibitor
16%
Blood Clotting Factor 11
16%
Cohort Study
7%
Thrombosis
7%
